Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial

ConclusionsGalcanezumab was not superior to rimegepant for the primary endpoint; however, both interventions demonstrated efficacy as preventive treatments in participants with episodic migraine. The efficacy and safety profiles observed in galcanezumab-treated participants were consistent with previous studies.Trial registrationClinTrials.gov —NCT05127486 (I5Q-MC-CGBD).
Source: Neurology and Therapy - Category: Neurology Source Type: research